PT  - JOURNAL ARTICLE
AU  - Robert Whittaker
AU  - Anja Bråthen Kristofferson
AU  - Elina Seppälä
AU  - Beatriz Valcarcel Salamanca
AU  - Lamprini Veneti
AU  - Margrethe Larsdatter Storm
AU  - Håkon Bøås
AU  - Nina Aasand
AU  - Umaer Naseer
AU  - Karoline Bragstad
AU  - Olav Hungnes
AU  - Reidar Kvåle
AU  - Karan Golestani
AU  - Siri Feruglio
AU  - Line Vold
AU  - Karin Nygård
AU  - Eirik Alnes Buanes
TI  - Trajectories of hospitalisation for patients infected with SARS-CoV-2 variant B.1.1.7 in Norway, December 2020 – April 2021
AID  - 10.1101/2021.06.28.21259380
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.28.21259380
4099  - http://medrxiv.org/content/early/2021/07/02/2021.06.28.21259380.short
4100  - http://medrxiv.org/content/early/2021/07/02/2021.06.28.21259380.full
AB  - Background The SARS-CoV-2 variant of concern (VOC) B.1.1.7 has spread worldwide and has been associated with increased risk of severe disease. Studies on patient trajectories and outcomes among hospitalised patients infected with B.1.1.7 are essential for hospital capacity planning.Methods Using linked individual-level data from national registries, we conducted a cohort study on cases of SARS-CoV-2 in Norway hospitalised between 21 December 2020 and 25 April 2021. We calculated adjusted hazard ratios using survival analysis to examine the association between B.1.1.7 and time from symptom onset to hospitalisation, and length of stay (LoS) in hospital and an intensive care unit compared to non-VOC. We calculated adjusted odds ratios using logistic regression to examine the association between B.1.1.7 and mortality (up to 30 days post discharge) compared to non-VOC.Results We included 946 B.1.1.7 patients and 157 non-VOC. The crude median time from symptom onset to hospitalisation was 8 days (IQR: 5–10) for B.1.1.7 and 8 days (IQR: 4–11) for non-VOC. The crude median LoS in hospital was 5.0 days (IQR: 2.6–10.0) for B.1.1.7 patients and 5.1 days (IQR: 2.5–9.9) for non-VOC. Fifty-four (6%) B.1.1.7 patients died, compared to 14 (9%) non-VOC. There was no difference in the unadjusted or adjusted estimates of our outcome measures for B.1.1.7 and non-VOC patients.Conclusions B.1.1.7 does not appear to influence hospitalised patient trajectories, compared to non-VOC. These findings, along with the success of ongoing vaccination programmes, are encouraging for ongoing capacity planning in the hospital sector.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was granted by Regional Committees for Medical Research Ethics - South East Norway, reference number 249509.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analysed during the current study come from the national emergency preparedness registry for COVID-19, housed at the Norwegian Institute of Public Health. The preparedness registry is temporary and comprises data from a variety of central health registries, national clinical registries and other national administrative registries. Further information on the preparedness registry, including access to data from each individual data source, is available at https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/. https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/